ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Dana-Farber Cancer Institute
- Study ID
- NCT02787369
- Phase
- PHASE1
- Status
- Active Not Recruiting
Conditions
- Recurrent Chronic Lymphoid Leukemia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ACY-1215 — DRUG
- Ibrutinib — DRUG
- Idelalisib — DRUG
Study Details
This research study is studying a drug called ACY-1215 in combination with ibrutinib or idelalisib as a possible treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).
Key Dates
- Start date
- May 31, 2016
- Status verified
- May 2026
- Primary completion
- Apr 30, 2026
- Completion
- Apr 30, 2027
Study Design
- Enrollment
- 3 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Combination of ACY-1215 With IbrutinibACY-1215 and Ibrutinib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.
- Experimental: Combination of ACY-1215 With IdelalisibACY-1215 and Idelalisib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.
Primary Outcome Measure
Determining Maximum Tolerated Dose [ Time Frame: 2 years ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | - |
Find similar trials in Boston, MA
By research site